We are dedicated to pushing the boundaries of pharmaceutical research by leveraging our robust Research Chemistry Platform and Specialty Chemistry ability. Our commitment to innovation positions us at the forefront of developing targeted protein degraders, a revolutionary approach that holds immense promise for treating a variety of diseases.
Overview of Targeted Protein Degraders
Targeted protein degraders represent a novel class of therapeutics that exploit the cell's natural protein disposal systems to eliminate disease-causing proteins. Unlike traditional inhibitors that merely block protein function, these degraders facilitate the complete removal of target proteins from the cell. They typically function through bifunctional molecules like proteolysis targeting chimeras (PROTACs) or molecular glues, which bring the target protein into proximity with an E3 ubiquitin ligase. This interaction tags the protein for degradation via the ubiquitin-proteasome pathway, leading to its efficient elimination. This mechanism opens new possibilities for targeting proteins that are considered "undruggable" by conventional means, expanding the therapeutic landscape significantly.
Our Services
By partnering with us, you gain access to an integrated suite of services designed to accelerate your targeted protein degrader program efficiently and effectively.
Target Identification and Validation
Our team assists in identifying and validating suitable protein targets for degradation. Utilizing advanced bioinformatics and assay development, we evaluate target feasibility and relevance to disease mechanisms, ensuring a strategic foundation for your project.
Degrader Design and Synthesis
We specialize in the design and synthesis of bifunctional molecules, including PROTACs and molecular glues. Our team expertly crafts specific linkers, such as polyethylene glycol (PEG) chains, and ligands like THAL-S, tailored to target proteins such as BCR-ABL, and selected E3 ligases like VHL or CRBN. This optimization enhances molecular interactions, ensuring effective degradation of the desired targets.
In Vitro Screening and Optimization
Our in vitro services include high-throughput screening to assess degrader efficacy. We perform cell-based assays to evaluate potency, selectivity, and cytotoxicity, providing detailed insights for lead optimization. Our iterative approach ensures that candidate molecules meet the necessary criteria for progression.
Structural Biology Support
Leveraging techniques like X-ray crystallography and cryo-electron microscopy, we elucidate the structural basis of degrader interactions with target proteins and E3 ligases. This structural insight guides the rational design of molecules with enhanced efficacy and specificity.
In Vivo Pharmacology
We offer in vivo studies to assess the pharmacokinetics, pharmacodynamics, and therapeutic potential of your degraders. Our expertise in animal models ensures relevant and translatable data, supporting the advancement of your candidates toward clinical evaluation.
Our Technologies and Methods
We employ a range of advanced technologies and methodologies to support targeted protein degradation projects. These technologies, combined with our scientific expertise, enable us to address the complex challenges inherent in developing targeted protein degraders.
High-Precision Proteomics
Our proteomics platforms enable quantitative analysis of protein expression and degradation. This technology allows us to monitor the impact of degraders on both target and off-target proteins, ensuring specificity and efficacy.
Molecular Modeling and Simulation
Using computational modeling, we simulate interactions between degraders, target proteins, and E3 ligases. This approach informs the design of molecules with optimal binding properties and guides structure-activity relationship (SAR) studies.
Structural Biology Techniques
Techniques such as X-ray crystallography and cryo-EM provide detailed structural information on protein complexes. Understanding the molecular architecture aids in refining degrader design for improved potency and selectivity.
Cell-Based Assays
We utilize advanced cell-based assays, including live-cell imaging and reporter systems, to assess degrader activity in a physiological context. These assays provide critical data on cellular uptake, target engagement, and functional outcomes.
Frequently Asked Questions
Q1: What makes targeted protein degraders different from traditional inhibitors?
Targeted protein degraders eliminate the entire protein rather than merely inhibiting its activity. This leads to a more sustained suppression of the protein's function and can overcome issues like drug resistance. Additionally, degraders can target proteins that lack enzymatic activity or have no suitable binding pockets for inhibitors.
Q2: Can you help with the selection of an appropriate E3 ligase for my project?
Yes, we can assist in selecting an E3 ligase that is most suitable for your target protein and cellular context. Our team considers factors such as ligase expression profiles, tissue specificity, and compatibility with the degrader design to ensure optimal efficacy.